IL11 and prostate carcinoma: Notably, upon neutralization of IL-11 signalling using an IL-11 antagonist, the expression and phosphorylation levels of JAK1 and STAT4 were markedly altered, substantiating the pivotal role of IL-11 in activation of the JAK/STAT pathway in prostate cancer (Fig. 7G).